As reported by Law360 (subscription), the parties in the Lovenox/Enox blood clot drug antitrust lawsuit have announced a $35 million settlement in the class action lawsuit brought on behalf of thousands of buyers of generic Lovenox (enoxaparin) that accused the company and Sandoz Pharmaceuticals of illegally conspiring to prevent other drug companies from competing in the sale of enoxaparin, used in the treatment of heart attacks and to prevent and control deep vein thrombosis.

The suit alleges that Momenta and Sandoz pharmaceutical companies improperly used a patented chemical test to prevent other drug manufacturers from producing other generic versions of Lovenox, thereby keeping prices unfairly and artificially high.

As Law360 notes, “The class will include thousands of hospitals, uninsured people and third-party buyers that indirectly bought brand-name Lovenox or generic enoxaparin in 29 states and Washington, D.C., between Sept. 21, 2011, and Sept. 30, 2015.”

Learn more about the Lovenox class action antitrust case.

Contact us

Use the form below to contact a lawyer at Lieff Cabraser.